Claimed effect · Cerebrolysin

Does Cerebrolysin help with cognition in vascular dementia?

C
Grade C — weak human evidenceCochrane review: 6 RCTs, 597 participants · effect size: small
Short answerWeak human evidence. Cochrane review: 6 RCTs, 597 participants: enough to be interesting, not enough to count on. Where an effect is seen it is a small effect. A small pooled benefit on cognitive scores, from trials the reviewers rated at high risk of bias and very low quality, with no new trials in a decade. Their own conclusion: if there are benefits, they may be too small to be clinically meaningful.

What the studies show

A small pooled benefit on cognitive scores, from trials the reviewers rated at high risk of bias and very low quality, with no new trials in a decade. Their own conclusion: if there are benefits, they may be too small to be clinically meaningful.

“Combining the MMSE and ADAS-cog+ data (three studies, 420 people), there was a beneficial effect of Cerebrolysin (SMD 0.36, 95% CI 0.13 to 0.58; very low-quality evidence).”

Verbatim, from the abstractCui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev, 2019;11:CD008900

A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.

  1. 1
    Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia.Cochrane Database Syst Rev, 2019;11:CD008900Six RCTs, 597 participants; very low-quality evidence.

In context

Cerebrolysin is a mixture of short peptides and amino acids extracted from pig brain, made in Austria and given as a course of daily intravenous infusions for stroke, dementia and brain injury in Russia, China, Eastern Europe and Asia. It is not approved in the United States, the United Kingdom or EU-wide. The Cochrane review of seven stroke trials found no effect on death and a doubling of non-fatal serious adverse events; the Cochrane review of six vascular-dementia trials found a small cognitive benefit on very low-quality evidence that may be too small to matter.

Cerebrolysin is approved in austria, russia, china and others; not us/uk/eu-wide. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Cerebrolysin proven to help with cognition in vascular dementia?
No. The human evidence is weak (Cochrane review: 6 RCTs, 597 participants); LYO grades it C.
What studies are behind the grade?
A small pooled benefit on cognitive scores, from trials the reviewers rated at high risk of bias and very low quality, with no new trials in a decade. Their own conclusion: if there are benefits, they may be too small to be clinically meaningful.
Is Cerebrolysin approved for this?
Cerebrolysin is an approved medicine (Approved in Austria, Russia, China and others; not US/UK/EU-wide); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Cerebrolysin

Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →